CTY
City Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.46
−4.20%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -2.9%
- EBITDA
- -0.8%
- EBIT
- +7.5%
- Net income
- +19.0%
- EPS
- —
- Free cash flow
- +17.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2020